Corporate ActionAug 3, 2026, 04:23 PM
Transcode Therapeutics Amends Preferred Stock Designation
AI Summary
Transcode Therapeutics, Inc. filed a Second Amended and Restated Certificate of Designation for its Series A and Series B Non-Voting Convertible Preferred Stock on August 3, 2026. This amendment, approved by a majority of preferred stockholders and the Board, removed the 60-day notice requirement for changing or waiving the beneficial ownership limitation. No other changes were made to the certificate, and no additional securities were issued.
Key Highlights
- Filed Second Amended and Restated Certificate of Designation on August 3, 2026.
- Amended Series A and Series B Non-Voting Convertible Preferred Stock terms.
- Removed 60-day notice for changing/waiving beneficial ownership limitation.
- Approved by majority of Preferred Stock holders and the Board of Directors.
- No other changes were made, and no new securities were issued.
Price Impact
More from RNAZ
Corporate ActionJul 17, 4:11 PM
Transcode Therapeutics Increases Series C Preferred Stock Ownership Limit
Business UpdateJun 18, 8:06 AM
TransCode Therapeutics Presents Oncology Pipeline and Strategy
Clinical TrialJun 3, 8:15 AM
TransCode Therapeutics Completes Phase 1a Trial; Reports Safety, Stabilization